8.61 USD
+0.02 (+0.23%)
8.61 USD
0 (0%)
Taking everything into account, YMAB scores 4 out of 10 in our fundamental rating. YMAB was compared to 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for YMAB as it has an excellent financial health rating, but there are worries on the profitability. YMAB is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year YMAB has reported negative net income.
In the past year YMAB has reported a negative cash flow from operations.
YMAB had negative earnings in each of the past 5 years.
In the past 5 years YMAB always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -18.96%, YMAB is in the better half of the industry, outperforming 77.59% of the companies in the same industry.
With an excellent Return On Equity value of -25.40%, YMAB belongs to the best of the industry, outperforming 80.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.96% | ||
| ROE | -25.4% | ||
| ROIC | N/A |
ROA(3y)-36.35%
ROA(5y)-45.09%
ROE(3y)-46.99%
ROE(5y)-56.89%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
YMAB has a better Gross Margin (81.78%) than 85.37% of its industry peers.
YMAB's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for YMAB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81.78% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.89%
GM growth 5YN/A
2. Health
2.1 Basic Checks
YMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for YMAB has been increased compared to 1 year ago.
The number of shares outstanding for YMAB has been increased compared to 5 years ago.
YMAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
YMAB has an Altman-Z score of 2.71. This is not the best score and indicates that YMAB is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of YMAB (2.71) is better than 69.81% of its industry peers.
There is no outstanding debt for YMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.71 |
ROIC/WACCN/A
WACC9.9%
2.3 Liquidity
A Current Ratio of 4.00 indicates that YMAB has no problem at all paying its short term obligations.
YMAB's Current ratio of 4.00 is in line compared to the rest of the industry. YMAB outperforms 45.74% of its industry peers.
YMAB has a Quick Ratio of 3.58. This indicates that YMAB is financially healthy and has no problem in meeting its short term obligations.
YMAB has a Quick ratio (3.58) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4 | ||
| Quick Ratio | 3.58 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 10.71% over the past year.
The Revenue has decreased by -1.34% in the past year.
Measured over the past years, YMAB shows a very strong growth in Revenue. The Revenue has been growing by 35.95% on average per year.
EPS 1Y (TTM)10.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)-1.34%
Revenue growth 3Y35.95%
Revenue growth 5YN/A
Sales Q2Q%-14.36%
3.2 Future
Based on estimates for the next years, YMAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.75% on average per year.
Based on estimates for the next years, YMAB will show a quite strong growth in Revenue. The Revenue will grow by 17.88% on average per year.
EPS Next Y-24.97%
EPS Next 2Y-19.37%
EPS Next 3Y-17.71%
EPS Next 5Y9.75%
Revenue Next Year-5.98%
Revenue Next 2Y3.28%
Revenue Next 3Y6.75%
Revenue Next 5Y17.88%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for YMAB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for YMAB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
YMAB's earnings are expected to decrease with -17.71% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.37%
EPS Next 3Y-17.71%
5. Dividend
5.1 Amount
YMAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
8.61
+0.02 (+0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners82.83%
Inst Owner Change-99.41%
Ins Owners0.34%
Ins Owner Change-971.94%
Market Cap391.24M
Revenue(TTM)85.39M
Net Income(TTM)-22.22M
Analysts53.75
Price Target8.2 (-4.76%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.27%
Min EPS beat(2)44.37%
Max EPS beat(2)74.16%
EPS beat(4)3
Avg EPS beat(4)25.03%
Min EPS beat(4)-18.84%
Max EPS beat(4)74.16%
EPS beat(8)5
Avg EPS beat(8)16.37%
EPS beat(12)9
Avg EPS beat(12)28.96%
EPS beat(16)10
Avg EPS beat(16)18.43%
Revenue beat(2)2
Avg Revenue beat(2)4.3%
Min Revenue beat(2)4.07%
Max Revenue beat(2)4.54%
Revenue beat(4)2
Avg Revenue beat(4)-4.6%
Min Revenue beat(4)-22.2%
Max Revenue beat(4)4.54%
Revenue beat(8)3
Avg Revenue beat(8)-3.53%
Revenue beat(12)7
Avg Revenue beat(12)4.86%
Revenue beat(16)7
Avg Revenue beat(16)0.93%
PT rev (1m)0%
PT rev (3m)-44.03%
EPS NQ rev (1m)3.14%
EPS NQ rev (3m)22.86%
EPS NY rev (1m)0%
EPS NY rev (3m)18.15%
Revenue NQ rev (1m)0.53%
Revenue NQ rev (3m)0.02%
Revenue NY rev (1m)0.45%
Revenue NY rev (3m)0.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.58 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.47 | ||
| P/tB | 4.59 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.5
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS1.88
BVpS1.93
TBVpS1.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.96% | ||
| ROE | -25.4% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81.78% | ||
| FCFM | N/A |
ROA(3y)-36.35%
ROA(5y)-45.09%
ROE(3y)-46.99%
ROE(5y)-56.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.89%
GM growth 5YN/A
F-Score4
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4 | ||
| Quick Ratio | 3.58 | ||
| Altman-Z | 2.71 |
F-Score4
WACC9.9%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-24.97%
EPS Next 2Y-19.37%
EPS Next 3Y-17.71%
EPS Next 5Y9.75%
Revenue 1Y (TTM)-1.34%
Revenue growth 3Y35.95%
Revenue growth 5YN/A
Sales Q2Q%-14.36%
Revenue Next Year-5.98%
Revenue Next 2Y3.28%
Revenue Next 3Y6.75%
Revenue Next 5Y17.88%
EBIT growth 1Y9.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-55.69%
EBIT Next 3Y-14.78%
EBIT Next 5YN/A
FCF growth 1Y60.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.1%
OCF growth 3YN/A
OCF growth 5YN/A
Y-MABS THERAPEUTICS INC / YMAB FAQ
What is the fundamental rating for YMAB stock?
ChartMill assigns a fundamental rating of 4 / 10 to YMAB.
What is the valuation status for YMAB stock?
ChartMill assigns a valuation rating of 0 / 10 to Y-MABS THERAPEUTICS INC (YMAB). This can be considered as Overvalued.
Can you provide the profitability details for Y-MABS THERAPEUTICS INC?
Y-MABS THERAPEUTICS INC (YMAB) has a profitability rating of 2 / 10.
What is the financial health of Y-MABS THERAPEUTICS INC (YMAB) stock?
The financial health rating of Y-MABS THERAPEUTICS INC (YMAB) is 7 / 10.